Global Information
회사소개 | 문의 | 비교리스트

세계의 성감염증(STD) 검사 시장 성장 기회와 산업 예측(2021-2030년) : 질환 종류별, 검사 로케이션별

Sexually Transmitted Diseases Testing Market by Disease Type and Location of Testing : Global Opportunity Analysis and Industry Forecast, 2021-2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059584
페이지 정보 영문 159 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 성감염증(STD) 검사 시장 성장 기회와 산업 예측(2021-2030년) : 질환 종류별, 검사 로케이션별 Sexually Transmitted Diseases Testing Market by Disease Type and Location of Testing : Global Opportunity Analysis and Industry Forecast, 2021-2030
발행일 : 2021년 12월 페이지 정보 : 영문 159 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 성감염증(STD) 검사 시장 규모는 2020년 914억 4,593만 달러에서 예측기간 중 5.1%의 CAGR로 확대되고, 2030년에는 1,504억 4,501만 달러 규모로 성장할 것으로 예측됩니다.

STD 검사 시장은 STD 이환 증가에 의해 지난 10년간 현저한 성장을 이루어 왔습니다. 높은 유병률에 의해 STD 진단 시설의 커버율도 선진국에서 크게 향상하고 있습니다. 한편 개발도상 지역에서 STD 진단 시설은 아직 불충분해, 이 지역의 큰 우려사항이 되고 있습니다.

세계의 성감염증(STD) 검사(Sexually Transmitted Diseases Testing) 시장을 조사했으며, 시장 정의와 개요, 시장 영향요인 분석, 시장 규모 추정과 예측, 질환 종류·검사 로케이션·지역/주요 국가 등 각종 세분화별 내역, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석
  • COVID-19의 영향 분석

제4장 성감염증(STD) 검사 시장 : 질환 종류별

  • 개요
  • 클라미디아
  • 임질
  • 단순포진바이러스
  • 매독
  • 인유두종바이러스(HPV)
  • 기타
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측

제5장 성감염증(STD) 검사 시장 : 검사 로케이션별

  • 개요
  • 실험실 검사
  • POC(Point of Care) 검사
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측

제6장 성감염증(STD) 검사 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 국가별
    • 시장 규모와 예측 : 질환 종류별
    • 시장 규모와 예측 : 검사 로케이션별

제7장 기업 개요

  • ABBOTT LABORATORIES
  • BECTON DICKINSON COMPANY
  • BIOMERIEUX, INC.
  • BIO-RAD LABORATORIES INC.
  • DANAHER CORPORATION
  • DIASORIN MOLECULAR LLC
  • HOLOGIC INC.
  • ORASURE TECHNOLOGIES, INC.
  • ROCHE HOLDINGS AG
  • THERMO FISHER SCIENTIFIC(AFFYMETRIX)
KSM 22.03.07

LIST OF TABLES

  • TABLE 01.STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 (MILLION TESTS)
  • TABLE 02.STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
  • TABLE 03.STD TESTING MARKET FOR CHLAMYDIA, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 04.STD TESTING MARKET FOR CHLAMYDIA, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.STD TESTING MARKET FOR GONORRHEA, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 06.STD TESTING MARKET FOR GONORRHEA, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.STD TESTING MARKET FOR HERPES SIMPLEX VIRUS, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 08.STD TESTING MARKET FOR HERPES SIMPLEX VIRUS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.STD TESTING MARKET FOR SYPHILIS, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 10.STD TESTING MARKET FOR SYPHILIS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.STD TESTING MARKET FOR HUMAN PAPILOMAVIRUS, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 12.STD TESTING MARKET FOR HUMAN PAPILOMAVIRUS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.STD TESTING MARKET FOR OTHER DISEASES, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 14.STD TESTING MARKET FOR OTHER DISEASES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 (MILLION TESTS)
  • TABLE 16.STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
  • TABLE 17.STD TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 18.STD TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.STD TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2020-2030 (MILLION TESTS)
  • TABLE 20.STD TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2020-2030 ($MILLION)
  • TABLE 21.GLOBAL STD TESTING MARKET, VOLUME (NO. OF TESTS, MILLION)
  • TABLE 22.GLOBAL STD TESTING MARKET, VALUE ($ MILLION)
  • TABLE 23.NORTH AMERICA STD TESTING MARKET, BY COUNTRY, 2020-2030 VOLUME ($MILLION)
  • TABLE 24.NORTH AMERICA STD TESTING MARKET, BY COUNTRY, 2020-2030 VALUE ($MILLION)
  • TABLE 25.NORTH AMERICA STD TESTING MARKET, BY DISEASE TYPE, VOLUME 2020-2030 ($MILLION)
  • TABLE 26.NORTH AMERICA STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
  • TABLE 27.NORTH AMERICA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
  • TABLE 28.NORTH AMERICA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
  • TABLE 29.EUROPE STD TESTING MARKET, BY COUNTRY, 2020-2030 VOLUME ($MILLION)
  • TABLE 30.EUROPE STD TESTING MARKET, BY COUNTRY, 2020-2030 VALUE ($MILLION)
  • TABLE 31.EUROPE STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VOLUME ($MILLION)
  • TABLE 32.EUROPE STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
  • TABLE 33.EUROPE STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
  • TABLE 34.EUROPE STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
  • TABLE 35.ASIA-PACIFIC STD TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 36.ASIA-PACIFIC STD TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 37.ASIA-PACIFIC STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VOLUME ($MILLION)
  • TABLE 38.ASIA-PACIFIC STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
  • TABLE 39.ASIA-PACIFIC STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
  • TABLE 40.ASIA-PACIFIC STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
  • TABLE 41.LAMEA STD TESTING MARKET, BY COUNTRY, 2020-2030 VOLUME ($MILLION)
  • TABLE 42.LAMEA STD TESTING MARKET, BY COUNTRY, 2020-2030 VALUE ($MILLION)
  • TABLE 43.LAMEA STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VOLUME ($MILLION)
  • TABLE 44.LAMEA STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
  • TABLE 45.LAMEA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
  • TABLE 46.LAMEA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
  • TABLE 47.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 48.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 49.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 50.BD: COMPANY SNAPSHOT
  • TABLE 51.BD: PRODUCT SEGMENTS
  • TABLE 52.BECTON DICKINSON COMPANY: PRODUCT PORTFOLIO
  • TABLE 53.BIOMERIEUX: COMPANY SNAPSHOT
  • TABLE 54.BIOMERIEUX: OPERATING SEGMENTS
  • TABLE 55.BIOMERIEUX: PRODUCT PORTFOLIO
  • TABLE 56.BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
  • TABLE 57.BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
  • TABLE 58.BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
  • TABLE 59.DANAHER: COMPANY SNAPSHOT
  • TABLE 60.DANAHER: OPERATING SEGMENTS
  • TABLE 61.DANAHER: PRODUCT PORTFOLIO
  • TABLE 62.DIASORIN: COMPANY SNAPSHOT
  • TABLE 63.DIASORIN: OPERATING SEGMENTS
  • TABLE 64.DIASORIN: PRODUCT PORTFOLIO
  • TABLE 65.HOLOGIC INC.: COMPANY SNAPSHOT
  • TABLE 66.HOLOGIC: OPERATING SEGMENTS
  • TABLE 67.HOLOGIC: PRODUCT PORTFOLIO
  • TABLE 68.ORASURE: COMPANY SNAPSHOT
  • TABLE 69.ORASURE: OPERATING SEGMENTS
  • TABLE 70.ORASURE: PRODUCT PORTFOLIO
  • TABLE 71.ROCHE: COMPANY SNAPSHOT
  • TABLE 72.ROCHE: OPERATING SEGMENTS
  • TABLE 73.ROCHE: PRODUCT PORTFOLIO
  • TABLE 74.THERMO FISHER SCIENTIFIC (AFFYMETRIX): COMPANY SNAPSHOT
  • TABLE 75.THERMO FISHER SCIENTIFIC (AFFYMETRIX): OPERATING SEGMENTS
  • TABLE 76.THERMO FISHER SCIENTIFIC (AFFYMETRIX): PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.STD TESTING MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.U.S. STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 14.CANADA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 15.MEXICO STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 16.GERMANY STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 17.FRANCE STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 18.UK STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 19.ITALY STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 20.REST OF EUROPE STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 21.JAPAN STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 22.CHINA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 23.INDIA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 24.REST OF ASIA-PACIFIC STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 25.LATIN AMERICA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 26.MIDDLE EAST AND AFRICA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
  • FIGURE 27.ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 29.ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 30.BECTON DICKINSON COMPANY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 31.BD COMPANY: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.BD COMPANY: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 33.BIOMERIEUX: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 35.BIOMERIEUX: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 36.BIO-RAD LABORATORIES INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 37.BIO-RAD LABORATORIES INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 38.BIO-RAD LABORATORIES INC.: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 39.DANAHER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 41.DANAHER: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 42.DIASORIN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.DIASORIN: REVENUE SHARE BY SEGMENT/TECHNOLOGY, 2020 (%)
  • FIGURE 44.DIASORIN: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 45.HOLOGIC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 46.HOLOGIC: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 47.HOLOGIC: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 48.ORASURE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 49.ORASURE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 50.ORASURE TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 51.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 52.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 53.THERMO FISHER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 54.THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 55.THERMO FISHER: REVENUE SHARE BY REGION, 2020 (%)

The STD testing market accounted for $91,445.93 million in 2020, and is expected to reach $1,50,445.01 million by 2030, registering a CAGR of 5.1% from 2021 to 2030. Sexually transmitted diseases (STDs) are considered as one of the most critical health challenges globally. Chlamydia, gonorrhea, and herpes simplex virus are some of the highly prevalent STDs. The STD testing market has witnessed significant growth in the past decade with increasing prevalence of STDs. With high prevalence, coverage of STD diagnosis facilities has also majorly increased in the developed countries. However, in developing regions, STD diagnosis facilities are still inadequate to provide wider coverage to the population with STDs. Inadequate facilities for STD diagnosis are the major concern in developing regions.

STDs have witnessed substantial growth in their prevalence and incidents in the past decade. With increasing prevalence, respective countries across the world are focusing on implementation of national screening programs to expand the coverage of STD diagnosis. Moreover, reimbursement policies have also been favorable for STD services. These factors are significantly driving the growth of the global STD testing market. On the other hand, limited access to STD diagnosis in developing regions is expected to restrain the market growth.

The STD testing market is segmented on the basis of disease type, location of testing, and region. By disease type, it is divided into chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus (HPV), human immunodeficiency virus testing, and others. By location of testing, the market is bifurcated into laboratory testing, and point of care (PoC) testing. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global STD Testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the products and end users of STD Testing used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Disease Type

  • Chlamydia
  • Gonorrhea
  • Herpes simplex virus
  • Syphilis
  • Human papillomavirus (HPV)
  • Other diseases (human immunodeficiency virus (HIV), chancroid, trichomoniasis, and hepatitis B)

By Location of Testing

  • Laboratory testing
  • Point of care (POC) testing
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • Italy
  • France
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East and Africa

KEY MARKET PLAYERS

  • Abbott laboratories
  • Becton Dickinson Company
  • BioMerieux, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Diasorin Molecular LLC
  • Hologic, Inc.
  • Orasure Technologies, Inc.
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits to Stakeholders
  • 1.3.Key market segments
    • 1.3.1.LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • 1.4.Research methodology
    • 1.4.1.SECONDARY RESEARCH
    • 1.4.2.PRIMARY RESEARCH
    • 1.4.3.ANALYST TOOLS AND MODELS

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.TOP INVESTMENT POCKETS
    • 3.2.2.TOP WINNING STRATEGIES
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.DRIVERS
      • 3.5.1.1.High prevalence and rise in incidences of STD across the world
      • 3.5.1.2.Implementation of national screening programs
      • 3.5.1.3.Supporting reimbursement for STDs testing
    • 3.5.2.RESTRAINTS
      • 3.5.2.1.Social stigma associated with patients visiting specialized STD clinics
      • 3.5.2.2.Huge proportion of patients infected with STDs in remote areas
      • 3.5.2.3.Stringent regulatory abidance requirements for the participants of STD market
    • 3.5.3.OPPORTUNITIES
      • 3.5.3.1.Decrease in number of visits to government clinics
      • 3.5.3.2.National screening programs across the globe
      • 3.5.3.3.Niche opportunities for technology and POC test providers in an emerging economy
    • 3.5.4.IMPACT ANALYSIS
  • 3.6.COVID-19 impact analysis on the STD testing market

CHAPTER 4:STD TESTING MARKET, BY DISEASE TYPE

  • 4.1.Overview
    • 4.1.1.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 4.2.Chlamydia
    • 4.2.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 4.2.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 4.3.Gonorrhea
    • 4.3.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 4.3.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 4.4.Herpes simplex virus
    • 4.4.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 4.4.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 4.5.Syphilis
    • 4.5.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 4.5.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 4.6.Human papillomavirus (HPV)
    • 4.6.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 4.6.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 4.7.Other diseases
    • 4.7.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 4.7.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)

CHAPTER 5:STD TESTING MARKET, BY LOCATION OF TESTING

  • 5.1.Overview
    • 5.1.1.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 5.2.Laboratory testing
    • 5.2.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 5.2.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)
  • 5.3.Point of care (POC) testing
    • 5.3.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 5.3.2.MARKET SIZE AND FORECAST (VOLUME AND VALUE)

CHAPTER 6:STD TESTING MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.MARKET SIZE AND FORECAST
  • 6.2.North America
    • 6.2.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 6.2.2.MARKET SIZE AND FORECAST, BY COUNTRY
      • 6.2.2.1.U.S.
      • 6.2.2.1.1.Market analysis.
      • 6.2.2.2.Canada
      • 6.2.2.2.1.Market analysis.
      • 6.2.2.3.Mexico
      • 6.2.2.3.1.Market analysis.
    • 6.2.3.NORTH AMERICA MARKET SIZE AND FORECAST, BY DISEASE TYPE
    • 6.2.4.NORTH AMERICA MARKET SIZE AND FORECAST, BY LOCATION OF TESTING
  • 6.3.Europe
    • 6.3.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 6.3.2.MARKET SIZE AND FORECAST, BY COUNTRY
      • 6.3.2.1.Germany
      • 6.3.2.1.1.Market analysis.
      • 6.3.2.2.France
      • 6.3.2.2.1.Market analysis.
      • 6.3.2.3.UK
      • 6.3.2.3.1.Market analysis.
      • 6.3.2.4.Italy
      • 6.3.2.4.1.Market analysis.
      • 6.3.2.5.Rest of Europe
      • 6.3.2.5.1.Market analysis.
    • 6.3.3.EUROPE MARKET SIZE AND FORECAST, BY DISEASE TYPE
    • 6.3.4.EUROPE MARKET SIZE AND FORECAST, BY LOCATION OF TESTING
  • 6.4.Asia-Pacific
    • 6.4.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 6.4.2.MARKET SIZE AND FORECAST, BY COUNTRY
      • 6.4.2.1.Japan
      • 6.4.2.1.1.Market analysis.
      • 6.4.2.2.China
      • 6.4.2.2.1.Market analysis.
      • 6.4.2.3.India
      • 6.4.2.3.1.Market analysis.
      • 6.4.2.4.Rest of Asia-Pacific
      • 6.4.2.4.1.Market analysis.
    • 6.4.3.ASIA-PACIFIC MARKET SIZE AND FORECAST, BY DISEASE TYPE
    • 6.4.4.ASIA-PACIFIC MARKET SIZE AND FORECAST, BY LOCATION OF TESTING
  • 6.5.LAMEA
    • 6.5.1.KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
    • 6.5.2.MARKET SIZE AND FORECAST, BY COUNTRY
    • 6.5.3.LATIN AMERICA
      • 6.5.3.1.1.Market analysis.
    • 6.5.4.MIDDLE EAST AND AFRICA
      • 6.5.4.1.1.Market analysis.
    • 6.5.5.LAMEA MARKET SIZE AND FORECAST, BY DISEASE TYPE
    • 6.5.6.LAMEA MARKET SIZE AND FORECAST, BY LOCATION OF TESTING

CHAPTER 7:COMPANY PROFILES

  • 7.1.ABBOTT LABORATORIES
    • 7.1.1.COMPANY OVERVIEW
    • 7.1.2.COMPANY SNAPSHOT
    • 7.1.3.OPERATING BUSINESS SEGMENTS
    • 7.1.4.PRODUCT PORTFOLIO
    • 7.1.5.BUSINESS PERFORMANCE
    • 7.1.6.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.2.BECTON DICKINSON COMPANY
    • 7.2.1.COMPANY OVERVIEW
    • 7.2.2.COMPANY SNAPSHOT
    • 7.2.3.OPERATING BUSINESS SEGMENTS
    • 7.2.4.PRODUCT PORTFOLIO
    • 7.2.5.BUSINESS PERFORMANCE
    • 7.2.6.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.3.BIOMERIEUX, INC.
    • 7.3.1.COMPANY OVERVIEW
    • 7.3.2.OPERATING BUSINESS SEGMENTS
    • 7.3.3.PRODUCT PORTFOLIO
    • 7.3.4.BUSINESS PERFORMANCE
    • 7.3.5.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.4.BIO-RAD LABORATORIES INC.
    • 7.4.1.COMPANY OVERVIEW
    • 7.4.2.COMPANY SNAPSHOT
    • 7.4.3.OPERATING BUSINESS SEGMENTS
    • 7.4.4.PRODUCT PORTFOLIO
    • 7.4.5.BUSINESS PERFORMANCE
    • 7.4.6.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.5.DANAHER CORPORATION
    • 7.5.1.COMPANY OVERVIEW
    • 7.5.2.COMPANY SNAPSHOT
    • 7.5.3.OPERATING BUSINESS SEGMENTS
    • 7.5.4.PRODUCT PORTFOLIO
    • 7.5.5.BUSINESS PERFORMANCE
    • 7.5.6.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.6.DIASORIN MOLECULAR LLC
    • 7.6.1.COMPANY OVERVIEW
    • 7.6.2.COMPANY SNAPSHOT
    • 7.6.3.OPERATING BUSINESS SEGMENTS
    • 7.6.4.PRODUCT PORTFOLIO
    • 7.6.5.BUSINESS PERFORMANCE
    • 7.6.6.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.7.HOLOGIC INC.
    • 7.7.1.COMPANY OVERVIEW
    • 7.7.2.COMPANY SNAPSHOT
    • 7.7.3.OPERATING BUSINESS SEGMENTS
    • 7.7.4.PRODUCT PORTFOLIO
    • 7.7.5.BUSINESS PERFORMANCE
    • 7.7.6.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.8.ORASURE TECHNOLOGIES, INC.
    • 7.8.1.COMPANY OVERVIEW
    • 7.8.2.OPERATING BUSINESS SEGMENTS
    • 7.8.3.PRODUCT PORTFOLIO
    • 7.8.4.BUSINESS PERFORMANCE
    • 7.8.5.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.9.ROCHE HOLDINGS AG
    • 7.9.1.COMPANY OVERVIEW
    • 7.9.2.COMPANY SNAPSHOT
    • 7.9.3.OPERATING BUSINESS SEGMENTS
    • 7.9.4.PRODUCT PORTFOLIO
    • 7.9.5.BUSINESS PERFORMANCE
    • 7.9.6.KEY STRATEGIC MOVES AND DEVELOPMENTS
  • 7.10.THERMO FISHER SCIENTIFIC (AFFYMETRIX)
    • 7.10.1.COMPANY OVERVIEW
    • 7.10.2.OPERATING BUSINESS SEGMENTS
    • 7.10.3.PRODUCT PORTFOLIO
    • 7.10.4.BUSINESS PERFORMANCE
    • 7.10.5.KEY STRATEGIC MOVES AND DEVELOPMENTS
Back to Top
전화 문의
F A Q